Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P50DA036114 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Johns Hopkins University | OTHER |
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine extended exposure to cigarettes varying in nicotine content among disadvantaged women. Disadvantaged women are at increased risk for smoking, nicotine dependence, and using high nicotine yield cigarettes and are also at significantly increased risk for smoking-related adverse health consequences, including cervical cancer, thrombosis related to hormone-based contraception, infertility, and early menopause. Studies testing an innovative regulatory strategy of reducing the nicotine content of cigarettes to a non-addictive level have shown promising beneficial effects (decreased smoking rate, reduced toxicant exposure, and increased cessation) in the general population of smokers. However, these studies have uniformly excluded vulnerable populations like disadvantaged women who may respond differently considering their greater vulnerability to smoking and nicotine dependence. Thus, little is known scientifically about how this highly vulnerable subgroup of smokers might respond to a nicotine reduction policy. This project is designed to address that substantial knowledge gap. This same study was also conducted in two additional vulnerable populations under a similar protocol.
The primary overall objective of these studies is to evaluate the effects of extended exposure to cigarettes differing in nicotine content in socioeconomically disadvantaged (< high school educational attainment) women of childbearing age using a 3-condition, parallel groups design. After a baseline period in which daily smoking rate and other baseline assessments are completed, participants will be randomly assigned to one of three cigarette conditions (nicotine content: 0.04, 2.4, and 15.8 mg nicotine/gram of tobacco) for the 12-week experimental period.
The cigarettes to be used in this study were made under an NIH contract with production being overseen by the Research Triangle Institute (referred to as "Spectrum cigarettes"). NIH currently has approximately 10 million of these cigarettes (of varying types) for research purposes. The cigarettes selected for the study span the range of yields likely to produce the hypothesized effects, as described above. The Spectrum cigarettes are not currently commercially available, although they are similar in many ways to marketed cigarettes (e.g., similar manufacturing, filter, paper, etc.).
The primary overall objective of this study is to evaluate the effects of extended exposure to cigarettes differing in nicotine content in female adult smokers of childbearing age (18-44 yrs) whose highest academic degree is high school using a 3-condition, parallel groups design. After a baseline period in which daily smoking rate and other baseline assessments are completed, participants will be randomly assigned to one of three cigarette conditions (nicotine content: 0.04 mg, 2.4 mg, and 15.8 mg nicotine/g of tobacco) for the 12-week experimental period.
Participants will be seen weekly throughout the 12-week experimental period to obtain research cigarettes. Cigarettes smoked per day will be obtained by participants completing daily Interactive Voice Response (IVR) reports of cigarettes in past 24 hours. This daily data will be used to calculate weekly means, with week-12 means serving as the primary outcome.
This same study was conducted in two additional vulnerable populations under a similar protocol, with differences between protocols consisting of data collection specific to that vulnerable population. This included information such as use and timing of opioid maintenance therapy for individuals with opioid-use disorder or additional assessments of anxiety and depression for individuals with affective disorders. In order to explore potential differences across individuals with different vulnerabilities, data from all three studies were combined for analysis. A vulnerable population-by-condition or population-by-condition-by-time interaction term was included in all analyses. In the event that these interaction terms were statistically significant, all pairwise comparisons were conducted using a Bonferroni multiple comparison adjustment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 0.8 mg nicotine | Experimental | 0.8 mg nicotine very low nicotine content cigarettes |
|
| 0.12 mg nicotine | Experimental | 0.12 mg nicotine very low nicotine content cigarettes |
|
| 0.03 mg nicotine | Experimental | 0.03 mg nicotine very low nicotine content cigarettes |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Very low nicotine content cigarettes | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cigarettes Per Day (CPD) | Participant reported number of cigarettes smoked per day at Week 12. | 12 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stephen T. Higgins, Ph.D. | University of Vermont | Study Director |
| Sarah H. Heil, Ph.D. | University of Vermont | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johns Hopkins University | Baltimore | Maryland | 21224 | United States | ||
| University of Vermont |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38236223 | Derived | Harfmann RF, Heil SH, Bunn JY, Snell LM, Tidey JW, Sigmon SC, Gaalema DE, Lee DC, Streck JM, Bergeria CL, Davis DR, Plucinski S, Higgins ST. Changes in weight among individuals with psychiatric conditions or socioeconomic disadvantage assigned to smoke very low nicotine content cigarettes. Exp Clin Psychopharmacol. 2024 Apr;32(2):181-188. doi: 10.1037/pha0000700. Epub 2024 Jan 18. | |
| 36208817 | Derived | Gaalema DE, Snell LM, Tidey JW, Sigmon SC, Heil SH, Lee DC, Bunn JY, Park C, Hughes JR, Higgins ST. Potential effects of nicotine content in cigarettes on use of other substances. Prev Med. 2022 Dec;165(Pt B):107290. doi: 10.1016/j.ypmed.2022.107290. Epub 2022 Oct 5. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 0.8 mg Nicotine | 0.8 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes |
| FG001 | 0.12 mg Nicotine | 0.12 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes |
| FG002 | 0.03 mg Nicotine | 0.03 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 0.8 mg Nicotine | 0.8 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes |
| BG001 | 0.12 mg Nicotine | 0.12 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Cigarettes Per Day (CPD) | Participant reported number of cigarettes smoked per day at Week 12. | Participants who completed Week 12. | Posted | Least Squares Mean | Standard Error | cigarettes per day | 12 weeks |
|
12 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 0.8 mg Nicotine | 0.8 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Sudden onset of chest pain due to not enough blood going to the heart | Cardiac disorders | CTCAE (5.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Infections and infestations | Infections and infestations | CTCAE (5.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Stephen T. Higgins, PhD, Professor, Department of Psychiatry | University of Vermont | 802-735-6267 | stephen.higgins@uvm.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Feb 9, 2018 | Oct 10, 2022 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D014029 | Tobacco Use Disorder |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
This study was one of three multi-site clinical trials conducted in three different vulnerable populations under a similar protocol, with differences between protocols consisting of data collection specific to that vulnerable population. This included information such as use and timing of opioid maintenance therapy for individuals with opioid-use disorder or additional assessments of anxiety and depression for individuals with affective disorders. In order to explore potential differences across individuals with different vulnerabilities, data from all three studies were combined for analysis. A vulnerable population-by-condition or population-by- condition-by-time interaction term was included in all analyses. In the event that these interaction terms were statistically significant, all pairwise comparisons were conducted using a Bonferroni multiple comparison adjustment. Please see Statistical Analysis Plan for more details.
Not provided
Not provided
Not provided
| Burlington |
| Vermont |
| 05401 |
| United States |
| 34255068 | Derived | Oliver AC, DeSarno M, Irvin CG, Kaminsky D, Tidey JW, Sigmon SC, Heil SH, Gaalema DE, Lee D, Bunn JY, Davis DR, Streck JM, Gallagher T, Higgins ST. Effects of Reduced Nicotine Content Cigarettes on Fractional Exhaled Nitric Oxide and Self-Reported Respiratory Health Outcomes Among Smokers With Psychiatric Conditions or Socioeconomic Disadvantage. Nicotine Tob Res. 2022 Jan 1;24(1):135-140. doi: 10.1093/ntr/ntab145. |
| 34242666 | Derived | Higgins ST, DeSarno M, Bunn JY, Gaalema DE, Leventhal AM, Davis DR, Streck JM, Harfmann RF, Markesich C, Orr E, Sigmon SC, Heil SH, Tidey JW, Lee D, Hughes JR. Cumulative vulnerabilities as a potential moderator of response to reduced nicotine content cigarettes. Prev Med. 2021 Nov;152(Pt 2):106714. doi: 10.1016/j.ypmed.2021.106714. Epub 2021 Jul 7. |
| 33079196 | Derived | Higgins ST, Tidey JW, Sigmon SC, Heil SH, Gaalema DE, Lee D, Hughes JR, Villanti AC, Bunn JY, Davis DR, Bergeria CL, Streck JM, Parker MA, Miller ME, DeSarno M, Priest JS, Cioe P, MacLeod D, Barrows A, Markesich C, Harfmann RF. Changes in Cigarette Consumption With Reduced Nicotine Content Cigarettes Among Smokers With Psychiatric Conditions or Socioeconomic Disadvantage: 3 Randomized Clinical Trials. JAMA Netw Open. 2020 Oct 1;3(10):e2019311. doi: 10.1001/jamanetworkopen.2020.19311. |
| 32628945 | Derived | Higgins ST, DeSarno M, Davis DR, Nighbor T, Streck JM, Adise S, Harfmann R, Nesheim-Case R, Markesich C, Reed D, Tyndale RF, Gaalema DE, Heil SH, Sigmon SC, Tidey JW, Villanti AC, Lee D, Hughes JR, Bunn JY. Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations. Prev Med. 2020 Nov;140:106189. doi: 10.1016/j.ypmed.2020.106189. Epub 2020 Jul 3. |
| Adverse Event |
|
| incarcerated |
|
| Withdrawal by Subject |
|
| Death |
|
| Physician Decision |
|
| Protocol Violation |
|
| Reason unknown |
|
| BG002 | 0.03 mg Nicotine | 0.03 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Cigarettes Per Day | Mean | Standard Deviation | Cigarettes Per Day |
|
0.03 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes |
|
|
|
| 0 |
| 254 |
| 13 |
| 254 |
| 241 |
| 254 |
| EG001 | 0.12 mg Nicotine | 0.12 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes | 1 | 235 | 4 | 235 | 203 | 235 |
| EG002 | 0.03 mg Nicotine | 0.03 mg nicotine very low nicotine content cigarettes Very low nicotine content cigarettes | 1 | 286 | 13 | 286 | 226 | 286 |
| Blurred vision | Eye disorders | CTCAE (5.0) | Systematic Assessment |
|
| Bloody Stool | Gastrointestinal disorders | CTCAE (5.0) | Systematic Assessment | Diarrhea, Stomach pain, Vomiting |
|
| Kidney infection | Infections and infestations | CTCAE (5.0) | Systematic Assessment | Cellulitis, Hepatitis B infection, Hepatitis C infection |
|
| Broken bone | Injury, poisoning and procedural complications | CTCAE (5.0) | Systematic Assessment | Bruising |
|
| Frontal lobe lesion | Investigations | CTCAE (5.0) | Systematic Assessment | Knee sprain |
|
| Diabetes Type 2 | Metabolism and nutrition disorders | CTCAE (5.0) | Systematic Assessment | Hyperglycemia |
|
| Tenosynovitis of Hand | Musculoskeletal and connective tissue disorders | CTCAE (5.0) | Systematic Assessment |
|
| Seizure | Nervous system disorders | CTCAE (5.0) | Systematic Assessment | Stroke |
|
| Anxiety, feelings of dread or danger | Psychiatric disorders | CTCAE (5.0) | Systematic Assessment | Depression, Thoughts of taking ones own life |
|
| Acute Renal Failure | Renal and urinary disorders | CTCAE (5.0) | Systematic Assessment |
|
| Skin graft to wound on leg | Skin and subcutaneous tissue disorders | CTCAE (5.0) | Systematic Assessment |
|
| Neurosurgery | Surgical and medical procedures | CTCAE (5.0) | Systematic Assessment | Hospitalization due to increased pain |
|
| High blood pressure | Vascular disorders | CTCAE (5.0) | Systematic Assessment |
|
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | CTCAE (5.0) | Systematic Assessment |
|
| Gastrointestinal disorders | Gastrointestinal disorders | CTCAE (5.0) | Systematic Assessment |
|
| General disorders | General disorders | CTCAE (5.0) | Systematic Assessment |
|
| Nervous system disorders | Nervous system disorders | CTCAE (5.0) | Systematic Assessment |
|
| Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | CTCAE (5.0) | Systematic Assessment |
|
| Vascular disorders | Vascular disorders | CTCAE (5.0) | Systematic Assessment |
|
| Surgical and medical procedures | Surgical and medical procedures | CTCAE (5.0) | Systematic Assessment |
|
| Injury, poisoning and procedural complications | Injury, poisoning and procedural complications | CTCAE (5.0) | Systematic Assessment |
|
Not provided
Not provided